% 0期刊文章% p·纽豪斯% k Kellar % p·爱森% h .白% k . Wesnes %一个e . Coderre % A普法夫%霍华德一个h·威尔金斯% D % E.D.莱文% T尼古丁的治疗轻度认知障碍% B 6个双盲试验临床试验% D R 10.1212 / WNL 2012%。0 b013e31823efcbb % 首页J神经病学% P 91 - 101 X % V 78% N 2%目的:初步评估经皮的尼古丁疗法的安全性和有效性认知表现和临床学科地位与轻度认知障碍(MCI)。方法:不吸烟被遗忘MCI被随机分配到皮肤尼古丁(每天15毫克或安慰剂)6个月。主要的结果变量是注意力改善评估与康纳斯连续性能测试(CPT),以临床临床改善全球印象,安全措施。二次措施包括计算机认知测试和病人和观察者的评级。结果:74名受试者中,39随机安慰剂尼古丁和35。67例(34尼古丁,33安慰剂)完成。主要的认知结果测量(CPT)显示显著身上观察到尼古丁诱导下。改善没有对医生评分显著影响全球的进步。二级结果测量显示重要nicotine-associated改善注意力、记忆、精神运动速度,改善被认知障碍的病人/线人评级。安全性和耐受性的皮肤尼古丁是优秀的。 Conclusion: This study demonstrated that transdermal nicotine can be safely administered to nonsmoking subjects with MCI over 6 months with improvement in primary and secondary cognitive measures of attention, memory, and mental processing, but not in ratings of clinician-rated global impression. We conclude that this initial study provides evidence for nicotine-induced cognitive improvement in subjects with MCI; however, whether these effects are clinically important will require larger studies. Classification of evidence: This study provides Class I evidence that 6 months of transdermal nicotine (15 mg/day) improves cognitive test performance, but not clinical global impression of change, in nonsmoking subjects with amnestic MCI. AD=Alzheimer disease; AE=adverse event; BMI=body mass index; CDR=Clinical Dementia Rating; CGIC=Clinical Global Impression of Change; CPT=Continuous Performance Test; CRT=Choice Reaction Time; MCI=mild cognitive impairment; OASR=Older Adult Self Report; OABCL=Older Adult Behavior Checklist; RT=reaction time %U //www.ez-admanager.com/content/neurology/78/2/91.full.pdf